TY - JOUR
T1 - Breast cancer stem cells
AU - Kai, Kazuharu
AU - Arima, Yoshimi
AU - Kamiya, Toshio
AU - Saya, Hideyuki
N1 - Funding Information:
This work was supported in part by the following NIH grants R01CA070896 , R01CA075503 , R01CA107382 , R01CA132115 , and R01CA086072 (R.G.P.). The Kimmel Cancer Center was supported by the NIH Cancer Center Core Grant P30CA56036 (to R.G.P.). This project is funded in part from the Marian C. Falk Medical Research Trust and a grant from the Pennsylvania Department of Health (R.G.P.).
PY - 2010/4
Y1 - 2010/4
N2 - Since the initial discovery of leukemia stem cells nearly a decade ago, a great deal of cancer research has focused on the identification of cancer stem cells (CSCs) in many types of solid tumors, including breast cancer. Through analysis of cell surface markers and xenotransplant models, a subpopulation of putative human breast cancer stem cells (BCSCs) that is CD24-negative/CD44- positive (CD24-/ CD44+) and bears high aldehyde dehydrogenase 1 activity has been isolated in clinical samples of breast cancer tissues. Human BCSCs are considered to be derived from basal cells that reside in the basal membranes of alveolar units in human adult mammary glands. Furthermore, BCSCs have been shown to express higher levels of oxidative stress-responsive genes, which could confer part of their ability to resist anti-cancer therapy, than non-CSCs. The emerging picture of the biological properties of BCSCs would contribute for devising innovative therapies for breast cancer, targeting the intrinsic and extrinsic factors that maintain the BCSCs.
AB - Since the initial discovery of leukemia stem cells nearly a decade ago, a great deal of cancer research has focused on the identification of cancer stem cells (CSCs) in many types of solid tumors, including breast cancer. Through analysis of cell surface markers and xenotransplant models, a subpopulation of putative human breast cancer stem cells (BCSCs) that is CD24-negative/CD44- positive (CD24-/ CD44+) and bears high aldehyde dehydrogenase 1 activity has been isolated in clinical samples of breast cancer tissues. Human BCSCs are considered to be derived from basal cells that reside in the basal membranes of alveolar units in human adult mammary glands. Furthermore, BCSCs have been shown to express higher levels of oxidative stress-responsive genes, which could confer part of their ability to resist anti-cancer therapy, than non-CSCs. The emerging picture of the biological properties of BCSCs would contribute for devising innovative therapies for breast cancer, targeting the intrinsic and extrinsic factors that maintain the BCSCs.
UR - http://www.scopus.com/inward/record.url?scp=77954702944&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77954702944&partnerID=8YFLogxK
U2 - 10.1007/s12282-009-0176-y
DO - 10.1007/s12282-009-0176-y
M3 - Review article
C2 - 19806428
AN - SCOPUS:77954702944
SN - 1340-6868
VL - 17
SP - 80
EP - 85
JO - Breast Cancer
JF - Breast Cancer
IS - 2
ER -
